Recombinant Type A Botulinum Toxin products have broad application prospects in healthcare applications. They are widely used in neurotherapy.
JHM is actively advancing the development of Recombinant Type A Botulinum Toxin with the aim of delivering superior and safer clinical solutions for patients. Current indications under development include:
Improvement of moderate to severe glabellar lines (frown lines)
In phase III clinical trial
Post-stroke upper limb spasms in adults
In phase III clinical trial
axillary hyperhidrosis, eyelid spasm, post-stroke lower limb spasms in adults
Obtain Phase II/III clinical trial approval
The global botulinum toxin market is vast and expanding rapidly, with significant potential across medical disciplines. In 2023, Botox®️ generated US$5.67 billion in global sales, securing its position among the world’s top 100 best-selling drugs.
In China, the botulinum toxin market is projected to experience sustained rapid growth, driven by the increasing number of approved products, enhanced consumer awareness and indication expansions. By 2030, the market is expected to reach CN¥39 billion.